Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled Imatinib (AER-901) in Healthy Volunteers
NCT04903730Phase 1Completed
- Sponsor
- Aerami Therapeutics
- Start
- May 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AER-901 in pulmonary arterial hypertension (PAH) (3 arms), sponsored by Aerami Therapeutics. Primary endpoints: Treatment Emergent Adverse Events and Serious Adverse Events. Started May 2021; status: completed.
02
Drugs
AER-901
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04903730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903730.